Pittsburgh-based generic drug maker Mylan Inc. will acquire the U.S. rights to injectable blood thinner Arixtra as well as the authorized generic from Aspen Global Inc. for up to $300 million.
Mylan is currently selling Arixtra in the U.S. through an interim distribution agreement with Aspen, while Apotex is selling the authorized generic -- which will transfer to Mylan by year end.
Arixtra, an anticoagulant drug, is indicated for the prevention of deep vein thrombosis, or DVT. With the acquisition of Arixtra, Mylan joins the busy market of oral alternatives to Warfarin, which includes Boehringer Ingelheim's recently-criticized Pradaxa and J&J's Xarelto.
Read the Nasdaq press release